tirzepatide hrv Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Microdosing

Vomiting: Occurs in about 5% to 9% of patients, compared to 2% on a placebo

doi: 10.1016/j.euroneuro.2017.08.433 24 LachGSchellekensHDinanTGCryanJF

As a once-weekly subcutaneous injection, tirzepatide works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways

The markings are more compressed, so precision is slightly lower than with smaller syringes

National Bureau of Statistics of China

This dual-action mechanism distinguishes it from older GLP-1-only medications and is a significant part of why many patients tend to see more consistent appetite regulation and metabolic effects